Although chLpMab-23-f exhibited ADCC activity and exerted a moderate antitumor effect against CHO/PDPN cells, chLpMab-23-f neither exhibited ADCC activity against PC-10 cells nor CDC activity against PDPN-expressing tumor cells [19]. Here, PDPN is linked to neoplasm.